Revenue Breakdown
Composition ()
No data
Revenue Streams
Rapid Micro Biosystems Inc (RPID) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product revenue, accounting for 60.9% of total sales, equivalent to $4.42M. Another important revenue stream is Service revenue. Understanding this composition is critical for investors evaluating how RPID navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Rapid Micro Biosystems Inc maintains a gross margin of 8.88%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -145.09%, while the net margin is -146.78%. These profitability ratios, combined with a Return on Equity (ROE) of -68.83%, provide a clear picture of how effectively RPID converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, RPID competes directly with industry leaders such as CMT and TAYD. With a market capitalization of $171.53M, it holds a significant position in the sector. When comparing efficiency, RPID's gross margin of 8.88% stands against CMT's 17.36% and TAYD's 47.05%. Such benchmarking helps identify whether Rapid Micro Biosystems Inc is trading at a premium or discount relative to its financial performance.
